Captor Therapeutics strengthens its scientific team and prepares for the launch of clinical trials in 2023 with the appointment of Dr. Robert Dyjas as Director of Medical Affairs and Clinical Development
Wroclaw, Poland, February 02, 2022 - Captor Therapeutics S.A. (WSE: CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, announces the strengthening of its scientific team and the acceleration of its preparation for the initiation of clinical trials in 2023 with the appointment of Dr. Robert Dyjas as Director of Medical Affairs and Clinical Development.
Dr. Dyjas joins Captor Therapeutics after a successful international career in cancer and auto-immune diseases, having spent over 3 years as Clinical Research Manager at Janssen-Cilag (part of Johnson & Johnson) and over 15 years at SGS Life Sciences Services, a leading Contract Research Organization, where he focused on clinical development in various indications including oncology and virology. Prior to joining Captor, Dr. Dyjas was Director of Clinical Research at OncoArendi Therapeutics.
As Director of Medical Affairs and Clinical Development, Dr. Dyjas will be responsible for the preparation, implementation, and substantive supervision of the clinical trials of drug candidates developed by the Company. This is a considerable strengthening of Captor’s scientific team, which has recently made significant progress in the development of its flagship projects: CT-01 and CT-03, and follows last year appointment of Paweł Dobrzański, PhD, as Biology Department Director.
“We are very pleased to announce that Robert Dyjas has joined Captor as our Medical and Clinical Development Director. His great experience in designing and overseeing first-in-human clinical trials is invaluable for us, especially in the situation of fast approaching the clinic with two programmes.,” commented Michał Walczak, Member of the Board and Chief Scientific Officer of Captor Therapeutics.
“I have no doubt that the TPD technology developed by Captor Therapeutics, the European leader in this sector, can contribute to what I and many in the pharmaceutical world consider to be the next therapeutic revolution. I believe in the vision of the company's development and the potential of the projects in its pipeline, so I am very happy that I will have the honor to lead the Clinical Development Department and look forward to delivering outstanding clinical data in indications with high unmet medical needs,” emphasized Dr. Robert Dyjas.
Dr. Dyjas has extensive experience in the process, design, implementation, and oversight of the execution of clinical trials, in particular with early phase innovative drug candidates in oncology, autoimmune diseases, infectious disease, and endocrinology, amongst others. He has a well-established understanding of the preparation and implementation of early clinical development processes for drug candidates, including experience in regulatory procedures, safety oversight of investigational drug preparations, report writing and interpretation of study results.
Dr. Dyjas gained experience in the clinical research and medical affairs departments of global pharmaceutical companies, including Boehringer Mannheim / Roche and Janssen Research, where he held the position of team leader for medical affairs. For more than 15 years, he worked at the global CRO SGS Life Science Services Belgium NV, an organization specializing in the implementation of early phase clinical trials, where in his last position he successfully created a European network of satellite early phase clinical trial units. From 2018 to 2021, Dr. Dyjas worked at OncoArendi Therapeutics, where he served as Director of Clinical Research and was responsible for overseeing the clinical development of the OATD-01 (partnered with Galapagos under the name GLPG4716) and OATD-02 molecules.
About Captor Therapeutics
Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide an optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.
More information on Captor Therapeutics is available at: http://www.captortherapeutics.com
For further information, please contact:
Polish Media and Investor relations:
Point of View
+48 694 400 787
International Investor Relations:
Guillaume van Renterghem
+41 (0)76 735 01 31